January 14, 2019 Columns by Ed Tobias MS News that Caught My Eye Last Week: Stimulator for Spasticity, Tysabri Dosing Trial, Mobility Devices Contest, Stem Cell Phase 2 Trial WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity I’m one of the many people with multiple sclerosis (MS) for whom spasticity is a significant problem. This is a nonmedicinal approach to dealing with it. I hope it doesn’t take too long to make this…
January 7, 2019 News by Santiago Gisler Biogen Starts Phase 3b Trial to Evaluate Tysabri Extended Interval Dosing in RRMS Patients Biogen announced the start of a global Phase 3b clinical trial to evaluate the efficacy and safety of extended interval dosing (EID) with Tysabri (natalizumab) in patients with relapsing-remitting multiple sclerosis (RRMS). Results of the six-week dosing interval will be compared with the approved standard interval dosing…
December 14, 2018 Columns by Ed Tobias Pregnancy, DMTs, and MS: A New Study Many years ago a woman I know who has multiple sclerosis (MS) became pregnant. After her child was born her MS became significantly worse. There have been many studies on the impact of pregnancy on someone with MS, with most concluding that the number of MS relapses are reduced…
October 5, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018 ā Biogen’s MS Treatments Found Safe, Effective in Clinical and Real-world Data Clinical data and real-world results support the long-term efficacy of Biogenās medications for multiple sclerosis (MS), according to scientific presentations being released by the company. Specifically, findings support the effectiveness ofĀ Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) used early in the disease’s course, as well as the…
September 26, 2018 News by Jose Marques Lopes, PhD DMTs Are Cost-Effective and Help to Slow MS Progression, 10-Year Study from UK Reports Four disease-modifying therapies (DMTs) for Ā multiple sclerosisĀ āĀ Avonex, Rebif, Betaferon, and CopaxoneĀ ā are cost-effective and reduce disease progression in MS patients, especially those with relapsing-remitting disease, according to 10-year, real-world results from U.K.ās MS Risk Sharing Scheme (RSS). But the long-term benefits observed wane over…
August 27, 2018 News by Iqra Mumal, MSc Test to Monitor Tysabri Levels in Relapsing MS Patients, moNATor by Abreos Biosciences, Available in US Abreos BiosciencesĀ announced the U.S. launch ofĀ moNATor, a laboratory-developed test that can help physicians monitor the levels ofĀ Tysabri (natalizumab) in patients with multiple sclerosis (MS). Tysabri (approved for relapsing forms of MS, by Biogen) administered at a dose of 300 mg every four weeks is known to be…
May 21, 2018 Columns by Ed Tobias MS News that Caught My Eye Last Week: PML Treatment, Gilenya for Kids, Rituximab, and an MS trial that is Enrolling Complications from Gilenya Treatment Managed Successfully, Case Report Says This wasn’t a minor complication. It was a version of PML, a brain disease that can be fatal. PML is also a known side effect of Tysabri, so the report of a successful treatment should be important to…
May 8, 2018 News by Alice MelĆ£o, MSc Rituximab Seen to Ably and Safely Treat Refractory RRMS Patients in French Study An approved lymphoma treatment,Ā rituximab was found to be effective and safe for relapsing-remitting multiple sclerosis (RRMS) patients whose active disease has failed to respond to immunosuppressive therapies, a retrospective French study reports. Published in the Multiple Sclerosis Journal in an article titled, āEfficacy of…
February 12, 2018 Columns by Ed Tobias MS News that Caught My Eye Last Week: 3rd Round of Lemtrada, Ampyra’s Possibilities, Long-term MD1003, Possible PML Treatment #ACTRIMS2018 ā Third Course of Lemtrada Improves Relapse, Disability in MS Patients, CARE-MS II Trial Shows The normal treatment regimen with Lemtrada is a series of two treatment courses, with the second infusion course given 12 months after the first. A “selling point” for this disease-modifying therapy (DMT) is…
February 9, 2018 Columns by Ed Tobias Good News for Tysabri Users Who Are JCV Positive One of the many disease-modifying therapies (DMTs) that I’ve been on over the many years of my treatment for MS is Tysabri (natalizumab). It worked well, holding the progression of my MS at bay for the several years that I received the infusions. I’d probably still be on it…
October 30, 2017 Columns by Ed Tobias MS News That Caught My Eye Last Week: #MSParis, Biotin, Tysabri, Lemtrada, Propionic Acid Reports There’s been a lot of interest in the treatments (including natural treatments) for progressive MS that were presented at the ECTRIMS-ACTRIMS conference in Paris last week. Here are a few of our reports involving that research. #MSParis2017 ā MedDayās High-Dose Biotin, MD1003, Improves Disability in Progressive MS…
August 1, 2017 News by Jose Marques Lopes, PhD Long-term Tysabri Treatment Improved Quality of Life and Satisfaction with Therapy in Relapsing MS Patients, Study Finds Long-term Tysabri (natalizumab) treatment of relapsing multiple sclerosis (RMS) improves physical and mental health and leads to greater satisfaction with therapy, new research shows. The study, āLong-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis,ā appeared in the journal…
February 17, 2016 News by Patricia Inacio, PhD For MS Patients, New Guidelines for Controlling Rare Brain Infection Risk Under Tysabri Treatment The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC), responsible for assessing and monitoring safety issues for human medicines, completedĀ a review on the risk for progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with the medicine Tysabri (natalizumab). The issued guidelines have the objective of minimizing patientsā risk.